In addition, novel CTLA4-free combinations such as Relatlimab, a human IgG4 LAG-3-blocking antibody in combination with nivolumab may also play a role in uveal melanoma treatment in the future [39]. This evidence concerns the gene CTLA4 and uveal melanoma.